Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal

Turn Therapeutics Inc.

2025-Q3 EPS reported -$0.13

Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.
Cash and equivalents $3.11M at Sept 30, 2025, up from $0.87M at Dec 31, 2024.
Closed global supply/development/license agreement with Medline for PermaFusion platform.
Started trading on Nasdaq under TTRX on Oct 8, 2025; appointed two new board members.
Commenced clinical trial of topical IL-36/IL-31 inhibitor for eczema.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.